Ricardo Rojas-GarcÃ-a

List of Publications by Year
in descending order

72 papers	4,064 citations	147801 31 h-index	128289 60 g-index
79 all docs	79 docs citations	79 times ranked	5454 citing authors

#	Article	IF	Citations
1	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
2	Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology, 2014, 82, 879-886.	1.1	285
3	Antibodies to contactinâ€1 in chronic inflammatory demyelinating polyneuropathy. Annals of Neurology, 2013, 73, 370-380.	5.3	279
4	Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Annals of Neurology, 2001, 49, 130-134.	5.3	236
5	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
6	Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e149.	6.0	205
7	Denervation-activated STAT3â€“IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis. Nature Cell Biology, 2018, 20, 917-927.	10.3	189
8	Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nature Reviews Neurology, 2017, 13, 533-547.	10.1	188
9	ALS: A bucket of genes, environment, metabolism and unknown ingredients. Progress in Neurobiology, 2016, 142, 104-129.	5.7	158
10	Cortactin autoantibodies in myasthenia gravis. Autoimmunity Reviews, 2014, 13, 1003-1007.	5.8	93
11	Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurology, 2016, 73, 1099.	9.0	90
12	Absence of Dysferlin Alters Myogenin Expression and Delays Human Muscle Differentiation â€œin Vitroâ€• Journal of Biological Chemistry, 2006, 281, 17092-17098.	3.4	88
13	Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology, 2020, 94, e1171-e1180.	1.1	88
14	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
15	Analysis of theC9orf72Gene in Patients with Amyotrophic Lateral Sclerosis in Spain and Different Populations Worldwide. Human Mutation, 2013, 34, 79-82.	2.5	85
16	Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Scientific Reports, 2017, 7, 14411.	3.3	62
17	Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. Journal of Neuroimmunology, 2016, 291, 82-88.	2.3	59
18	CSF sAPPÎ², YKL-40, and NfL along the ALS-FTD spectrum. Neurology, 2018, 91, e1619-e1628.	1.1	59

#	Article	IF	Citations
19	Analysis of theCHCHD10gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	7.6	56
20	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	54
21	Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain, 2021, 144, 1183-1196.	7.6	46
22	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain, 2019, 142, 1121-1133.	7.6	45
23	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 162-168.	1.9	44
24	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 597-609.	3.7	44
25	Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 74-84.	3.0	43
26	Amyotrophic lateral sclerosis in Catalonia: A population based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 278-283.	1.7	42
27	Muscle imaging in muscle dystrophies produced by mutations in the EMD and LMNA genes. Neuromuscular Disorders, 2016, 26, 33-40.	0.6	40
28	Serum neurofilament light chain predicts long-term prognosis in Guillain-BarrÃ© syndrome patients. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 70-77.	1.9	40
29	Clinical characteristics and outcomes of thymomaâ€associated myasthenia gravis. European Journal of Neurology, 2021, 28, 2083-2091.	3.3	39
30	Distal hereditary motor neuropathies: Mutation spectrum and genotypeâ€“phenotype correlation. European Journal of Neurology, 2021, 28, 1334-1343.	3.3	39
31	Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 576-585.	1.9	38
32	Genotypeâ€“phenotype correlations in recessive titinopathies. Genetics in Medicine, 2020, 22, 2029-2040.	2.4	35
33	Analysis of Serum miRNA Profiles of Myasthenia Gravis Patients. PLoS ONE, 2014, 9, e91927.	2.5	35
34	RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis. Arthritis Research and Therapy, 2017, 19, 174.	3.5	34
35	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	30
36	Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. Scientific Reports, 2020, 10, 4308.	3.3	26

#	Article	IF	Citations
37	Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy. Scientific Reports, 2019, 9, 6155.	3.3	20
38	Cortical microstructure in the amyotrophic lateral sclerosisâ€“frontotemporal dementia continuum. Neurology, 2020, 95, e2565-e2576.	1.1	19
39	Autoantibody screening in Guillainâ€“BarrÃ© syndrome. Journal of Neuroinflammation, 2021, 18, 251.	7.2	19
40	Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies. Annals of Clinical and Translational Neurology, 2018, 5, 559-569.	3.7	18
41	Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. Journal of Neuropathology and Experimental Neurology, 2018, 77, 703-709.	1.7	18
42	Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 333-340.	1.7	17
43	Clinical and serological features of acute sensory ataxic neuropathy with antiganglioside antibodies. Journal of the Peripheral Nervous System, 2012, 17, 158-168.	3.1	15
44	Amyotrophic lateral sclerosis: A higher than expected incidence in people over 80 years of age. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 522-527.	1.7	15
45	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
46	Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	15
47	Antibodies against disialosyl and terminal NeuNAc(Î±2-3)Gal ganglioside epitopes in acute relapsing sensory ataxic neuropathy. Journal of Neurology, 2008, 255, 764-766.	3.6	13
48	No evidence for a large difference in ALS frequency in populations of African and European origin: A population based study in inner city London. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 66-68.	2.1	13
49	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	3.7	13
50	Drugâ€refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Annals of Clinical and Translational Neurology, 2022, 9, 122-131.	3.7	13
51	Thrombospondin-1 mediates muscle damage in brachio-cervical inflammatory myopathy and systemic sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	12
52	Comprehensive Care of Amyotrophic Lateral Sclerosis Patients: A Care Model. Archivos De Bronconeumologia, 2013, 49, 529-533.	0.8	11
53	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 124, 428-438.	4.4	11
54	Antibodies against nodo-paranodal proteins are not present in genetic neuropathies. Neurology, 2020, 95, e427-e433.	1.1	11

#	Article	IF	Citations
55	Bulbar involvement in patients with antiganglioside antibodies against NeuNAc(Â2-3)Gal. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 623-628.	1.9	10
56	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. Brain Pathology, 2021, 31, e12942.	4.1	9
57	Motor neuron involvement expands the neuropathological phenotype of lateâ€onset ataxia in RFC1 mutation (CANVAS). Brain Pathology, 2022, 32, e13051.	4.1	9
58	Paraproteinemic neuropathies. Presse Medicale, 2013, 42, e225-e234.	1.9	8
59	Chronic sensorimotor polyradiculopathy with antibodies to P2: An electrophysiological and immunoproteomic analysis. Muscle and Nerve, 2008, 38, 933-938.	2.2	6
60	Late onset Sandhoff disease presenting with lower motor neuron disease and stuttering. Neuromuscular Disorders, 2021, 31, 769-772.	0.6	6
61	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Frontiers in Neurology, 2021, 12, 750543.	2.4	6
62	A novel antiganglioside specificity against terminal NeuNAc(alfa 2â€“3)Gal in acute bulbar palsy. Journal of Neuroimmunology, 2006, 176, 219-222.	2.3	5
63	Effect of MAPK Inhibition on the Differentiation of a Rhabdomyosarcoma Cell Line Combined With CRISPR/Cas9 Technology: An In Vitro Model of Human Muscle Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 964-972.	1.7	5
64	A new de novo SYT2 mutation presenting as distal weakness. Neuropathy or neuromuscular junction dysfunction?. Journal of the Peripheral Nervous System, 2021, 26, 113-117.	3.1	5
65	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 45, 220-231.	1.5	4
66	Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Annals of Neurology, 2001, 49, 130-134.	5.3	4
67	Severe exacerbation of Andersenâ€“Tawil syndrome secondary to thyrotoxicosis. Journal of Human Genetics, 2014, 59, 465-466.	2.3	3
68	Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. PLoS ONE, 2019, 14, e0212647.	2.5	2
69	Pachymeningitis, Painful Ophthalmoplegia, and Multiple Cranial Neuropathy of Presumed Tuberculous Origin. Neuro-Ophthalmology, 2011, 35, 289-292.	1.0	1
70	Transthyretin-related hereditary amyloid polyneuropathy presenting with large fibre involvement and cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 64-65.	3.0	1
71	P3â€394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P1248.	0.8	0
72	Transcriptome characterization of the motor cortex suggests microglialâ€related key events due to TDPâ€43 aberrant inclusions. Alzheimer's and Dementia, 2020, 16, e042953.	0.8	0